A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals
對於Recursion Pharmaceuticals，我們來仔細看一下4位分析師的推薦意見。
The standing of Recursion Pharmaceuticals among...Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Recursion Pharmaceuticals (NASDAQ:RXRX) in the last three months.
在過去三個月中，有4位分析師就Recursion Pharmaceuticals (NASDAQ: RXRX) 發表了從看好到看淡不同的觀點評級。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
以下表格總結了他們最近的評級，揭示了過去30天內情緒的變化，並將其與前幾個月進行了比較。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.0, a high estimate of $11.00, and a low estimate of $6.00. Observing a downward trend, the current average is 18.18% lower than the prior average price target of $11.00.
分析師的12個月目標價位顯示，平均目標價爲9.0美元，最高估價爲11.00美元，最低估價爲6.00美元。觀察到價格呈下跌趨勢，當前平均價位比之前的11.00美元的目標價位低了18.18%。
Diving into Analyst Ratings: An In-Depth Exploration
深入探討分析師評級：分析師評級的深度探討
The standing of Recursion Pharmaceuticals among...
通過對最近分...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間